Lipella's Q3 Loss Narrows, But Cash Dwindles Amid Zero Revenue

TL;DR

**LIPO is burning cash with no revenue, and its going concern warning means this biotech is a high-risk bet.**

AI Summary

Lipella Pharmaceuticals Inc. reported a net loss of $1,254,078 for the three months ended September 30, 2025, a decrease from the $1,444,637 net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $3,888,087, compared to $3,574,592 in the prior year. Total revenues for the three months ended September 30, 2025, were $0, a significant drop from $80,380 in 2024, while nine-month revenues decreased to $216,117 from $362,691. Research and development expenses decreased to $720,973 for the quarter from $1,046,693 in 2024, but general and administrative expenses rose to $553,299 from $493,102. The company's cash and cash equivalents stood at $1,855,771 as of September 30, 2025, down from $2,184,863 at December 31, 2024. An accumulated deficit of $19,228,194 at September 30, 2025, and continued operating losses raise substantial doubt about the company's ability to continue as a going concern.

Why It Matters

Lipella's continued operating losses and an accumulated deficit of over $19 million signal significant financial instability, posing a high risk for investors. The complete absence of revenue in Q3 2025, compared to $80,380 in the prior year, highlights a critical challenge in monetizing its clinical-stage biotechnology programs. For employees, this raises concerns about job security and the company's long-term viability. Customers, particularly those awaiting new drug developments, face uncertainty regarding product timelines. In the broader market, this performance underscores the inherent risks of investing in early-stage biotech companies heavily reliant on external funding and successful clinical trials, especially when facing a competitive landscape with established pharmaceutical players.

Risk Assessment

Risk Level: high — The company explicitly states "substantial doubt about the Company's ability to continue as a going concern" due to an accumulated deficit of $19,228,194 and a net loss of $3,888,087 for the nine months ended September 30, 2025. Cash and cash equivalents decreased to $1,855,771 from $2,184,863, and the company had zero grant revenues for the three months ended September 30, 2025.

Analyst Insight

Investors should exercise extreme caution and consider divesting, as the company's going concern warning and lack of revenue indicate severe financial distress. New investors should avoid LIPO until a clear path to sustainable revenue and profitability is demonstrated, backed by significant capital infusion.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$1,254,078

eps

N/A

gross Margin

N/A

cash Position

$1,855,771

revenue Growth

-100.0%

Revenue Breakdown

Key Numbers

• $1,254,078 — Net Loss (Q3 2025) (Decreased from $1,444,637 in Q3 2024)
• $3,888,087 — Net Loss (YTD Sep 2025) (Increased from $3,574,592 in YTD Sep 2024)
• $0 — Total Revenues (Q3 2025) (Significant decrease from $80,380 in Q3 2024)
• $216,117 — Total Revenues (YTD Sep 2025) (Decreased from $362,691 in YTD Sep 2024)
• $19,228,194 — Accumulated Deficit (Increased from $15,340,107 at Dec 31, 2024)
• $1,855,771 — Cash and Cash Equivalents (Decreased from $2,184,863 at Dec 31, 2024)
• 4,620,837 — Common Stock Shares Outstanding (As of November 13, 2025)
• $720,973 — Research and Development Expenses (Q3 2025) (Decreased from $1,046,693 in Q3 2024)
• $553,299 — General and Administrative Expenses (Q3 2025) (Increased from $493,102 in Q3 2024)

Key Players & Entities

• LIPELLA PHARMACEUTICALS INC. (company) — registrant
• Dr. Jonathan Kaufman (person) — Chief Executive Officer
• National Institute of Health (company) — source of grant revenues
• SEC (regulator) — Securities and Exchange Commission
• Bloomberg (company) — publisher

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company reported a net loss of $1,254,078 for Q3 2025 and an accumulated deficit of $19,228,194. With cash reserves of $1,855,771 and continued operating losses, there is substantial doubt about Lipella's ability to continue as a going concern.
• Declining Revenue Trend [high — financial]: Total revenues for Q3 2025 were $0, a stark contrast to $80,380 in the prior year. Year-to-date revenues also fell by 40.4% to $216,117. This sharp decline raises concerns about the company's revenue-generating capabilities.
• Increased G&A Expenses [medium — operational]: General and administrative expenses increased by 12.2% to $553,299 in Q3 2025, compared to $493,102 in Q3 2024. This rise, coupled with declining revenues, suggests potential inefficiencies in operational cost management.
• Erosion of Cash Reserves [medium — financial]: Cash and cash equivalents decreased from $2,184,863 at the end of 2024 to $1,855,771 as of September 30, 2025. This 15.0% reduction indicates a significant burn rate relative to available cash.
• Growing Accumulated Deficit [high — financial]: The accumulated deficit has grown to $19,228,194, an increase of $3,888,087 for the nine-month period. This highlights the company's long-standing inability to achieve profitability.
• R&D Spending Reduction [medium — operational]: Research and development expenses decreased by 31.1% to $720,973 in Q3 2025 from $1,046,693 in Q3 2024. While this reduces immediate cash outflow, it could signal a slowdown in innovation or pipeline development.

Industry Context

Lipella Pharmaceuticals operates in the highly competitive and capital-intensive pharmaceutical industry, which is characterized by long development cycles, significant R&D investment, and stringent regulatory oversight. Companies in this sector often face challenges in revenue generation until products gain market approval and traction. The current environment demands continuous innovation and efficient operational management to navigate clinical trials, regulatory hurdles, and market access.

Regulatory Implications

As a pharmaceutical company, Lipella is subject to extensive regulation by bodies like the FDA. Failure to meet regulatory standards for drug development, manufacturing, or marketing can lead to significant delays, fines, or product withdrawal. The company's financial struggles could also impact its ability to fund necessary compliance activities and clinical trials required for regulatory approval.

What Investors Should Do

1. Monitor cash burn rate closely: Given the declining cash reserves and lack of revenue, investors should track the company's ability to fund operations and potential future financing needs.
2. Scrutinize R&D pipeline progress: Assess the status and potential of Lipella's drug development pipeline to understand future revenue prospects and the impact of reduced R&D spending.
3. Evaluate management's strategy for revenue generation: With zero revenue in the latest quarter, investors need clarity on the company's plan to achieve commercial viability and reverse the negative financial trends.
4. Assess going concern risk: Investors should consider the high probability of the company requiring additional funding or facing insolvency if operational performance does not improve significantly.

Key Dates

• 2025-09-30: End of Q3 2025 — Reported $0 revenue for the quarter and a net loss of $1,254,078, with cash reserves of $1,855,771.
• 2025-11-13: Common Stock Shares Outstanding reported — 4,620,837 shares outstanding as of this date, relevant for per-share calculations and market capitalization.
• 2024-09-30: End of Q3 2024 — Reported $80,380 revenue and a net loss of $1,444,637, providing a comparison point for current performance.
• 2024-12-31: End of Fiscal Year 2024 — Company had $2,184,863 in cash and cash equivalents and an accumulated deficit of $15,340,107.

Glossary

Accumulated Deficit

The cumulative net losses of a company since its inception, minus any accumulated profits. It represents a negative retained earnings balance. (Indicates the company has historically operated at a loss, with the deficit growing to $19,228,194 as of Q3 2025.)

Going Concern

An accounting assumption that a business will continue to operate for the foreseeable future. If substantial doubt exists, it must be disclosed. (The report explicitly states substantial doubt about Lipella's ability to continue as a going concern due to ongoing losses and declining cash.)

Net Loss

The total expenses of a company exceed its total revenues over a specific period. (Lipella reported significant net losses in both Q3 2025 ($1,254,078) and year-to-date ($3,888,087), highlighting its unprofitability.)

Cash and Cash Equivalents

Highly liquid short-term investments that can be readily converted into cash. (Represents the company's immediate liquidity. A decrease to $1,855,771 raises concerns about funding future operations.)

Research and Development Expenses

Costs incurred by a company in the process of developing new products or services, or improving existing ones. (A decrease in R&D spending ($720,973 in Q3 2025) could impact future innovation, though it also reduces current expenses.)

General and Administrative Expenses

Costs associated with the overall management and administration of a business, not directly tied to production or sales. (An increase in G&A expenses ($553,299 in Q3 2025) is concerning given the company's financial performance.)

Year-Over-Year Comparison

Compared to the prior year's comparable periods, Lipella Pharmaceuticals has experienced a significant downturn. Total revenues for Q3 2025 plummeted to $0 from $80,380 in Q3 2024, and year-to-date revenues decreased by 40.4%. While net losses have slightly narrowed year-over-year for the quarter ($1,254,078 vs $1,444,637), the year-to-date net loss has widened. R&D expenses have decreased, but G&A expenses have risen, contributing to the overall financial pressure.

Key Financial Figures

• $0.0001 — he registrant's common stock, par value $0.0001 per share, outstanding. Lipella Pharm

Filing Documents

• g084988_10q.htm (10-Q) — 1008KB
• g084988_ex31-1.htm (EX-31.1) — 15KB
• g084988_ex31-2.htm (EX-31.2) — 15KB
• g084988_ex32-1.htm (EX-32.1) — 8KB
• g084988_ex32-2.htm (EX-32.2) — 8KB
• 0001753926-25-001805.txt ( ) — 4882KB
• lipo-20250930.xsd (EX-101.SCH) — 40KB
• lipo-20250930_cal.xml (EX-101.CAL) — 39KB
• lipo-20250930_def.xml (EX-101.DEF) — 127KB
• lipo-20250930_lab.xml (EX-101.LAB) — 332KB
• lipo-20250930_pre.xml (EX-101.PRE) — 252KB
• g084988_10q_htm.xml (XML) — 724KB

Financial Statements

Financial Statements. 1 Condensed Balance Sheets as of September 30, 2025 (Unaudited) and December 31, 2024 1 Condensed Statements of Operations (Unaudited) for the Three Months and Nine months Ended September 30, 2025 and 2024 2 Condensed Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) for the Three and Nine months Ended September 30, 2025 and 2024 3 Condensed Statements of Cash Flows (Unaudited) for the Nine months Ended September 30, 2025 and 2024 4 Notes to Condensed Financial Statements (Unaudited) 5 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. 16 Item 3. Quantitative and Qualitative Disclosures About Market Risk. 27 Item 4.

Controls and Procedures

Controls and Procedures. 27 Part II. OTHER INFORMATION 28 Item 1. Legal Proceedings. 28 Item 1A. Risk Factors. 28 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. 29 Item 3. Defaults upon Senior Securities. 29 Item 4. Mine Safety Disclosures. 29 Item 5. Other Information. 29 Item 6. Exhibits. 30

Signatures

Signatures 31 PART I. FINANCIAL INFORMATION Item 1. Financial Statements. Lipella Pharmaceuticals Inc. CONDENSED BALANCE SHEETS September 30, 2025 (unaudited) December 31, 2024 Assets Current Assets Cash and cash equivalents $ 1,855,771 $ 2,184,863 Grants receivable — 84,713 Prepaid expenses 223,517 347,676 Total Current Assets 2,079,288 2,617,252 Property and Equipment Furniture, fixtures and equipment 140,294 140,294 Furniture, fixtures and equipment (Accumulated Depreciation) ( 132,595 ) ( 130,430 ) Furniture and fixtures, net 7,699 9,864 Other Assets Operating lease right of use asset 262,823 46,754 Total Assets 2,349,810 2,673,870 Liabilities and Stockholders' Equity Current liabilities Accounts payable 462,892 388,191 Accrued expenses 34,938 237,886 Operating lease liability 44,267 47,605 Payroll liability 100,302 80,735 Total Current Liabilities 642,399 754,417 Operating lease liability, net of current portion 219,816 — Total Liabilities 862,215 754,417 Stockholders' equity: Preferred stock, $ 0.0001 par value per share, 20,000,000 shares authorized; Series B preferred stock, $ 0.0001 par value per share, 72,000 shares authorized; 1,260 shares issued and outstanding at September 30, 2025 and 25,975 shares issued and outstanding at December 31, 2024 $ 1 $ 3 Series C preferred stock, $ 0.0001 par value per share, 1,050,000 shares authorized; 0 shares issued and outstanding at September 30, 2025 and 303,041 shares issued and outstanding at December 31, 2024 — 30 Common stock, $ 0.0001 par value per share, 200,000,000 shares authorized, 4,620,837 shares issued and outstanding at September 30, 2025 and 1,208,919 shares issued and outstanding at December 31, 2024 462 121 Additional paid-in capital 20,715,326 17,259,406 Accumulated deficit ( 19,228,194 ) ( 15,340,107 ) Total stockholders' equity 1,487,595 1,919,453 Total liabilities and stockho

View Full Filing

View this 10-Q filing on SEC EDGAR